Ultragenyx (RARE) Moves Before Friday’s Bell
Ultragenyx Pharmaceutical Inc. was up in premarket trade Friday after Cantor Fitzgerald raised its price target on the company and flagged its late-stage Angelman syndrome program. Shares finished Thursday at $23.71, gaining 1.45%, and were at $24.06 at 7:50 a.m. Eastern in the extended session. Cantor lifted its price target on Ultragenyx to $96 from $84 and stayed at Overweight, the bank’s way of saying it sees the stock topping the peer group. The firm also raised its success odds for GTX-102, Ultragenyx’s Angelman syndrome therapy candidate, bumping the probability to 60% from 25%.